Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma

Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma - Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011893

Enrollment

Registered

2013-09-28

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients over 20 years old 2. Patients diagnosed unresectable or metastatic renal cell carcinoma who have already treated at least with 1 TKI 3. Patients who understand the study and signed the informed consent forms

Exclusion criteria

Exclusion criteria: 1. Patients in contraindication 2. Patients with hepatic function disorder 3. Patients diagnosed as interstitial pneumonia 4. Patients who have already treated with Everolimus 5. Patients who are judged as inadequate by doctor in attendance

Design outcomes

Primary

Measure	Time frame
The relationship between efficacy and blood concentration of Everolimus	—

Secondary

Measure	Time frame
The relationship between adverse events and blood concentration of Everolimus	—

Countries

Japan

Contacts

Public ContactKoichi Tsutahara

Osaka General Medical Center Department of Urology

tsutahara@gh.opho.jp06-6692-1201

Outcome results